Mobile health firm DocGo's Q3 revenue beats estimates

DocGo

10/11/2025 21:33

Overview

DocGo Q3 2025 revenue beats analyst expectations despite a 49% yr/yr decline

Adjusted EBITDA loss for Q3 2025 beats analyst estimates

Net loss in Q3 2025 due to $16.7 mln non-cash impairments

Company achieves record volumes across all major business lines

Outlook

DocGo expects full-year 2025 revenue of $315-$320 mln

Company anticipates full-year 2026 revenue of $280-$300 mln

DocGo forecasts full-year 2025 adjusted EBITDA loss of $25-$28 mln

Company projects full-year 2026 adjusted EBITDA loss of $15-$25 mln

Result Drivers

MIGRANT PROGRAM WIND-DOWN - Revenue decline attributed to wind-down of migrant-related programs, impacting overall results

CORE BUSINESS GROWTH - Excluding migrant-related programs, revenue increased 8% in core business lines

RECORD VOLUMES - Achieved record volumes across all major business lines, with notable increases in care gap closure and transitions of care

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Beat
$70.81 mln
$70 mln (7 Analysts)
Q3 EPS
-$0.28
Q3 Net Income
-$29.70 mln
Q3 Adjusted EBITDA
Beat
-$7.20 mln
-$8.62 mln (7 Analysts)
Q3 Gross Margin
20.00%


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the healthcare facilities & services peer group is "buy"

Wall Street's median 12-month price target for DocGo Inc is $3.00, about 63% above its November 7 closing price of $1.11

Press Release: ID:nBw5XRJhja

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)